Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).~* Males or females at least 4 years of age.~* No flare-up symptoms within the past 4 weeks, including at the time of enrollment.~* Abstinent or using two highly effective forms of birth control.~* Accessible for treatment and follow-up; able to undergo all study procedures including low-dose WBCT (excluding head) without sedation.~Key Exclusion Criteria:~* Weight \<10 kg.~* Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.~* Amylase or lipase \>2x above the upper limit of normal (ULN) or with a history of chronic pancreatitis.~* Elevated aspartate aminotransferase or alanine aminotransferase \>2.5x ULN.~* Fasting triglycerides \>400 mg/dL with or without therapy.~* Female subjects who are breastfeeding.~* Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.~* Simultaneous participation in another clinical research study (other than palovarotene studies) within 4 weeks prior to Screening; or within five half-lives of the investigational agent, whichever is longer.~* Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palovarotene Chronic/Flare-Up Regimen (Type: EXPERIMENTAL): Participants received 5 mg palovarotene once daily for up to 48 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)

Based on this trial design, predict the completion outcome and termination type (if applicable).